Dyne Therapeutics (DYN) Share-based Compensation (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Share-based Compensation data on file, last reported at $13.1 million in Q1 2026.

• On a quarterly basis, Share-based Compensation changed 0.47% year-over-year to $13.1 million in Q1 2026; TTM through Mar 2026 was $37.4 million, a 3.98% decrease from a year earlier, with the FY2025 full-year figure at $45.9 million, down 36.93% from the prior year.
• Share-based Compensation for Q1 2026 stood at $13.1 million, up from $11.2 million in the prior quarter.
• Over the last five years, Share-based Compensation for DYN reached as high as $48.3 million in Q3 2025 and fell as low as $100000.0 in Q2 2025.
• Historically, Share-based Compensation has averaged $9.8 million across 5 years, with a median of $5.7 million in 2023.
• On a YoY basis, Share-based Compensation climbed as much as 452.32% in 2025 and fell as far as 98.52% in 2025.
• Year by year, Share-based Compensation stood at $3.8 million in 2022, then soared by 49.53% to $5.7 million in 2023, then soared by 82.84% to $10.5 million in 2024, then grew by 7.15% to $11.2 million in 2025, then rose by 16.52% to $13.1 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $13.1 million in Q1 2026, $11.2 million in Q4 2025, and $48.3 million in Q3 2025.